Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies

Inclusion Criteria

• •Men and women aged ≥ 18 years
• •Patient with metastatic or unresectable melanoma
• •Anti-PD1 monoclonal antibodies treatment indication
• •Patient affiliated to a social security regime
• •Signed Written Informed Consent.
• •agree with the storage of his biological samples
• •Women of childbearing potential must as mentioned in the summary of product characteristics (SPC) using two effective methods of contraception during treatment, and men whose partner is of childbearing potential must use effective contraception during treatment. For all patients treated men and women, contraception should be continued during the four months following the discontinuation of nivolumab.